Cabergoline, marketed under the pharmaceutical brand name Dostinex and manufactured by Pfizer, is a long acting ergot derived dopamine agonist with FDA approval for hyperprolactinaemia treatment. Contributing one of the most extensively documented clinical literature bases of any prolactin regulating compound, with a well established pharmacokinetic profile spanning several decades of neuroendocrine research. Pfizer’s pharmaceutical manufacturing origin distinguishes this formulation from research grade Cabergoline preparations, providing the quality, purity, and consistency standards of licensed pharmaceutical production. This formulation delivers 0.5mg per tablet in an 8 count pack; a compact format suited to research protocols requiring precise low frequency dosing consistent with Cabergoline’s exceptionally long half-life.

Cabergoline’s half-life of approximately 63 to 68 hours is the defining pharmacokinetic characteristic that distinguishes it from Pramipexole within CSD’s dopamine agonist range. Where Pramipexole requires more frequent administration due to its shorter half-life, Cabergoline’s extended active window enables twice weekly dosing in documented clinical research protocols while maintaining continuous D2 receptor engagement at pituitary lactotroph cells. This prolonged receptor occupancy produces sustained prolactin suppression from infrequent administrations, making Cabergoline the most practically manageable dopamine agonist for extended prolactin regulation research protocols and the most frequently referenced dopaminergic compound in hyperprolactinaemia research literature.

Cabergoline’s D2 receptor selectivity profile differs from Pramipexole’s in a research relevant way. Pramipexole’s exceptionally high D3 receptor affinity alongside D2 activity produces a dual limbic and pituitary dopaminergic research profile. Cabergoline’s primary activity is more specifically concentrated at pituitary D2 receptors producing potent, sustained prolactin suppression with a more targeted neuroendocrine activity profile and less pronounced limbic D3 receptor engagement than Pramipexole. This receptor selectivity distinction makes Cabergoline and Pramipexole complementary rather than interchangeable research tools in comparative dopamine agonist studies. Cabergoline providing the more prolactin focused, long acting pituitary D2 reference compound, Pramipexole providing the shorter acting dual D2/D3 comparative option.

Pfizer Dostinex is stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity before being made available, with COA documentation available on request. CSD stocks both Cabergoline and Pramipexole in the dopamine agonist prolactin regulation range, giving researchers access to both long acting ergot derived and shorter acting non ergot D2/D3 agonist mechanisms from a single verified Canadian supplier. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.

Store in a cool, dry place away from direct light and heat. Intended for research purposes only.

Commonly researched alongside Pramipexole in comparative dopamine agonist and prolactin regulation studies. Browse CSD’s full hormone research range for complete sourcing.